Skip to main content
. 2019 Mar 7;4(5):e123130. doi: 10.1172/jci.insight.123130

Figure 7. FGF21 is not required for CANA-induced improvement in glucose tolerance, activation of fatty acid oxidation and ketogenesis, reduction in hepatic steatosis, and transcriptional reprogramming.

Figure 7

(A) Urinary glucose after 6 weeks of CANA (n = 6–9/group). (B) Blood glucose, random fed (n = 7–9/group). (C) Intraperitoneal glucose tolerance test (1 g/kg) after overnight fast (n = 7–9/group). (D) Insulin tolerance test (n = 7–9/group). (E) Respiratory exchange ratio (n = 7–9/group). (F) Serum ketones after 16-hour fast (n = 7–9/group). (G) Quantification of hepatic steatosis by histology scoring. (H and I) qPCR of regulatory genes for fatty acid oxidation, ketogenesis, glucose metabolism, lipogenesis, and gluconeogenesis in liver (n = 6–8/group). P values (1- or 2-way ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; @@P < 0.01 in WT vs. FGF21 KO; !P < 0.05 in WT vs. WT + CANA; #P < 0.05 in FGF21 KO vs. FGF21 KO + CANA; $P < 0.05 in WT+ CANA vs. KO + CANA.